Citi says a share overhang has been removed after Larimar Therapeutics (LRMR) announced it has received FDA alignment on an accelerated approval pathway for nomlabofusp in Friedreich’s ataxia. The news removes a key overhang and reinforces Citi’s view of favorable risk/reward for the shares, which are trading well below cash, the analyst tells investors in a research note. The firm would be buyers on the post-earnings weakness and keeps a Buy rating on the name with a $14 price target
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.